HomeCompareEGHSF vs PFE

EGHSF vs PFE: Dividend Comparison 2026

EGHSF yields 7.22% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGHSF wins by $54289.41M in total portfolio value
10 years
EGHSF
EGHSF
● Live price
7.22%
Share price
$11.89
Annual div
$0.86
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54289.46M
Annual income
$52,883,345,113.88
Full EGHSF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — EGHSF vs PFE

📍 EGHSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGHSFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGHSF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EGHSF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGHSF
Annual income on $10K today (after 15% tax)
$614.12/yr
After 10yr DRIP, annual income (after tax)
$44,950,843,346.80/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, EGHSF beats the other by $44,950,821,026.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGHSF + PFE for your $10,000?

EGHSF: 50%PFE: 50%
100% PFE50/50100% EGHSF
Portfolio after 10yr
$27144.75M
Annual income
$26,441,685,686.30/yr
Blended yield
97.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

EGHSF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
4.0
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGHSF buys
0
PFE buys
0
No recent congressional trades found for EGHSF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGHSFPFE
Forward yield7.22%6.13%
Annual dividend / share$0.86$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$54289.46M$49.6K
Annual income after 10y$52,883,345,113.88$26,258.71
Total dividends collected$54193.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: EGHSF vs PFE ($10,000, DRIP)

YearEGHSF PortfolioEGHSF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,145$1,445.00$9,153$693.39+$3.0KEGHSF
2$16,275$3,280.27$8,593$849.25+$7.7KEGHSF
3$25,631$8,216.58$8,336$1,066.78+$17.3KEGHSF
4$51,612$24,186.64$8,437$1,384.80+$43.2KEGHSF
5$146,259$91,033.89$9,013$1,875.40+$137.2KEGHSF
6$638,689$482,191.80$10,306$2,680.72+$628.4KEGHSF
7$4,619,198$3,935,801.36$12,820$4,101.38+$4.61MEGHSF
8$58,148,066$53,205,523.46$17,673$6,826.70+$58.13MEGHSF
9$1,314,124,080$1,251,905,649.90$27,543$12,591.86+$1314.10MEGHSF
10$54,289,457,880$52,883,345,113.88$49,560$26,258.71+$54289.41MEGHSF

EGHSF vs PFE: Complete Analysis 2026

EGHSFStock

Enghouse Systems Limited, together with its subsidiaries, develops enterprise software solutions worldwide. It operates through two segments, Interactive Management Group and Asset Management Group. The Interactive Management Group segment provides customer interaction software and services to facilitate remote work, enhance customer service, increase efficiency, and manage customer communications across various types of interactions, including voice, email, web chats, text, and video. Its technologies include contact center, video collaboration, interactive voice response, outbound dialers, attendant console, agent performance optimization, business intelligence, and analytics that deployed in private cloud, multi-tenant cloud, or on-premise environments. This segment serves insurance companies, telecoms, banks, business process service providers, as well as technology and health care companies. The Asset Management Group segment offers a portfolio of software and services to cable operators, network telecommunication providers, media, transit, defense, and public safety companies. This segment's products include network infrastructure, operations support systems, and business support systems, as well as video and cloud TV solutions. This segment also provides fleet routing, dispatch, scheduling, transit e-ticketing and automated fare collection, communications, and emergency control center solutions for the transportation, government, first responders, distribution, and security sectors. Enghouse Systems Limited was incorporated in 1984 and is headquartered in Markham, Canada.

Full EGHSF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this EGHSF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGHSF vs SCHDEGHSF vs JEPIEGHSF vs OEGHSF vs KOEGHSF vs MAINEGHSF vs JNJEGHSF vs MRKEGHSF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.